ID

37414

Beschrijving

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin; ODM derived from: https://clinicaltrials.gov/show/NCT02429258

Link

https://clinicaltrials.gov/show/NCT02429258

Trefwoorden

Versies (1)
  1. 24-07-19 24-07-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

24 juli 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type II Diabetes NCT02429258

Engels

Eligibility Type II Diabetes NCT02429258

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus (t2dm)
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
Beschrijving

Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0456683
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [2,4]
C0456683
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
Beschrijving

Hemoglobin A1c measurement

Datatype

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) < or = to 45 kg/m2
Beschrijving

Body mass index

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
Beschrijving

Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime

Datatype

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025598
UMLS CUI [4]
C0557978
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
Beschrijving

Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral

Datatype

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0332300
UMLS CUI [2,3]
C0021641
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0332300
UMLS CUI [3,3]
C0935929
UMLS CUI [3,4]
C1527415
use of sulfonylureas during the 8 weeks prior to screening
Beschrijving

Sulfonylureas

Datatype

boolean

Alias
UMLS CUI [1]
C0038766
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
Beschrijving

Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor

Datatype

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C2353951
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C3273807
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
Beschrijving

Pharmaceutical Preparations Affecting Glucose metabolism

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0596620
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
Beschrijving

Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription

Datatype

boolean

Alias
UMLS CUI [1,1]
C0376606
UMLS CUI [1,2]
C0278329
UMLS CUI [2,1]
C0376606
UMLS CUI [2,2]
C0013231
Terug naar het begin van de pagina

Similar models

Eligibility Type II Diabetes NCT02429258

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes mellitus (t2dm)
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity
Item
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
C0021641 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) < or = to 45 kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime
Item
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0557978 (UMLS CUI [4])
Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral
Item
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
boolean
C0021641 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C0021641 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0332300 (UMLS CUI [3,2])
C0935929 (UMLS CUI [3,3])
C1527415 (UMLS CUI [3,4])
Sulfonylureas
Item
use of sulfonylureas during the 8 weeks prior to screening
boolean
C0038766 (UMLS CUI [1])
Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor
Item
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
boolean
C0332157 (UMLS CUI [1,1])
C2353951 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C3273807 (UMLS CUI [2,2])
Pharmaceutical Preparations Affecting Glucose metabolism
Item
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription
Item
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
boolean
C0376606 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C0376606 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial